Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 17, Issue 11, Pages 1769-1776Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.11.1769
Keywords
angiogenesis; heparanase; heparan sulfate; hepatocellular carcinoma; melanoma; lung cancer; PI-88; prostate cancer; vascular-endothelial growth factors
Categories
Ask authors/readers for more resources
Growth factors that stimulate angiogenesis are vital in tumor development and maintenance. Inhibitors of angiogenesis are emerging as key elements in anticancer treatments, and now antibodies and small molecule kinase inhibitors are approved in the treatment of a variety of solid tumors. These have shown modest but statistically significant benefit in colon, breast and lung cancers. PI-88 has a novel mechanism of action compared to the drugs on the market today. By inhibiting heparanase, PI-88 blocks angiogenesis on several different cellular and biological levels. Promising results from Phase I/II trials are being seen with PI-88 in a variety of tumor types including melanoma and hepatocellular carcinoma. However, the development of antibody-induced thrombocytopenia has limited its use in some patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available